First CCR5 Blocker Gets Vote of Approval An advisory committee to the FDA has voted unanimously to recommend the approval of Pfizer’s Celsentri® (maraviroc), an HIV entry inhibitor (EI) that targets the CCR5 receptor on CD4 cells.
April 19, 2007
Natural Molecule in Blood Blocks HIV A new paper published in the journal Cell indicates that researchers have isolated yet another natural ingredient in human blood that effectively blocks the binding of HIV to CD4 cells.
April 13, 2007
571 on ADAP Waiting Lists As of March 2007, four states have reported waiting lists for their ADAPs totaling 571 HIV-positive people in need, according to the 2007 National ADAP Monitoring Project Report.
April 10, 2007
Home HIV Test in the Works OraSure Technologies is looking to petition the U.S. Food and Drug Administration (FDA) to approve the assay for over-the-counter availability and home testing.
Rabies: An HIV Therapy? New research suggests that the virus responsible for rabies may play a significant role in the development of a vaccine to help treat HIV.
April 06, 2007
48-Week Prezista Data Published The Lancet has published final data from two key clinical trials of Prezista? (darunavir), Tibotec’s new protease inhibitor, indicating that the drug offers prolonged treatment effects for HIV-positive people with limited treatment options.
April 05, 2007
Large Study Links Meth Use and HIV Risk New study results have established methamphetamine use as an independent risk factor for HIV transmission and, when combined with other risk factors like unprotected receptive anal intercourse with multiple partners, the chances of seroconversion increases substantially.
April 02, 2007
GSK Reports Combivir and Ziagen Tampering Third-party tampering has resulted in misbranding of Ziagen® tablets as Combivir® tablets and employed counterfeit labels for Combivir tablets. GlaxoSmithKline is recommended that all Combivir and Ziagen users check their meds.
More Treatment News
Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.
